About Aldagen
Aldagen is a Healthcare company based in Durham (United States) founded in 2001, and was acquired by Nuo Therapeutics in February 2012. Regenerative cell therapies for vascular disorders. Aldagen has raised $61.53 million across 9 funding rounds from investors including Square 1 Bank, Harbert Management and Nuo Therapeutics. The company has 18 employees. Its chief executive, as recorded, is Tom Amick. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Drugs and Diversified. Its legal entity is ALDAGEN, INC. Its competitors include Tenaya Therapeutics, Cellino and MyoKardia; 3 of its 3 listed competitors have raised funding.
Company details
Aldagen was founded in 2001 in Durham, United States, focusing on regenerative medicine. Proprietary technology was utilized to isolate mesenchymal stem cells from patient bone marrow for treating vascular conditions. Clinical trials were conducted for candidates addressing critical limb ischemia, ischemic heart failure, and ischemic stroke. The company was acquired by Cytomedix, now Nuo Therapeutics, in February 2012.
- Headquarters Durham, United States
- Employees 18
- Stage Acquired
- SectorsHealthcare
- Website aldagen.com
- Social LinkedIn
- Acquired by Nuo Therapeutics (Feb 2012)
- Legal Name Aldagen, Inc.
- Total Equity Funding$61.53M (USD)
in 9 rounds
- Latest Funding Round$585K (USD), Series C
Jan 2012
- InvestorsSquare 1 Bank
& 10 more
- Employee Count18
- Acquired byNuo Therapeutics
(Feb 2012)
Funding Insights of Aldagen
Aldagen has successfully raised a total of $61.53M across 9 strategic funding rounds. The most recent funding activity was a Series C round of $585 thousand completed in January 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $61.53M
- Total Rounds 9
- Last Round Series C — $585,004
- First Round $6M
(Feb 2002)
- Investors Count 10
All 9 funding rounds of Aldagen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2012 | $585,004 | Series C | – | – | – |
| Jun 2011 | $1.08M | Series C | – | – | – |
| Nov 2009 | $7.29M | Series C | – | – | – |
| Apr 2008 | $18.4M | Series C | – | – | |
| Sep 2007 | $9M | Series C | – | – | |
| Dec 2006 | $14.3M | Series C | – | Harbert Management, Intersouth Partners | |
| Dec 2006 | $3M | Debt – Conventional | – | – | |
| Mar 2003 | $4.88M | Series A | – | – | – |
| Feb 2002 | $6M | Series A | – | – | – |
11 investors in total: 11 institutional.
Investors in Aldagen
Aldagen has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Square 1 Bank, Harbert Management and Nuo Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage life sciences and tech focused VC firm funding companies in the US | intersouth.com | Durham, United States | ||
Infrastructure, hedge, private equity, and debt fund focused on multiple sectors | 1993 | harbert.net | Birmingham, United States | |
| aurorafunds.com | ||||
Healthcare investments are made by Tullis Health Investors. | tullisfunds.com | Palm Beach Gardens, United States | ||
Wealth is managed for the Clark family by Clark Enterprises. | clarkenterprises.com | Bethesda, United States | ||
| trelys.com | ||||
FinTech & Media focused seed and early stage VC firm investing in the US | villageventures.com | Williamstown, United States | ||
Seed and early stage tech and life sciences focused VC firm funding companies in the US and Europe | talloakscapital.com | Charlottesville, United States | ||
Angel Network | 2001 | piedmontangelnetwork.com | Winston-salem, United States | |
Venture debt, treasury, and cash management services are provided. | 2005 | square1bank.com | Durham, United States |
Investor details for Aldagen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Aldagen
1 people are tracked at Aldagen (1 in leadership); the tracked headcount is 18.
| Name | Role | Group |
|---|---|---|
Tom Amick | CEO & President | Leadership |
Complete people profiles for Aldagen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Aldagen
4 dated milestones of Aldagen across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Aldagen is founded.
- Funding First funding round of $6.0M.
- Funding Latest funding round, Series C, of $585K.
- Exit Acquired by Nuo Therapeutics.
Competitors of Aldagen
Aldagen has 3 listed competitors in our database, 3 of them funded. They include Tenaya Therapeutics, Cellino and MyoKardia.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tenayatherapeutics.com | 2016 | San Francisco, United States | $142M | 140 | Regenerative and gene therapeutics for heart failure are developed. | |
| cellinobio.com | 2017 | Cambridge, United States | $125M | 63 | Developer of autologous cell therapies | |
| myokardia.com | 2012 | San Francisco, United States | $98M | 224 | Specialized drugs are developed for genetic heart diseases. |
Detailed competitors of Aldagen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cell Therapy
3 companies that operate in the same segment as Aldagen (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aldagen
Complete news archive for Aldagen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aldagen
Aldagen was founded in 2001 and raised its 1st funding round 1 year after it was founded.
Aldagen is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Tom Amick is the CEO of Aldagen, as recorded in our data.
Aldagen is a funded company, having raised a total of $61.53M across 9 funding rounds to date. The company's 1st funding round was a Series A of $6M, raised on Feb 2002.
Aldagen has 18 employees.
Aldagen was founded in 2001 in Durham, United States, focusing on regenerative medicine. Proprietary technology was utilized to isolate mesenchymal stem cells from patient bone marrow for treating vascular conditions. Clinical trials were conducted for candidates addressing critical limb ischemia, ischemic heart failure, and ischemic stroke. The company was acquired by Cytomedix, now Nuo Therapeutics, in February 2012.
Aldagen's top competitors include Tenaya Therapeutics, Cellino and MyoKardia.
Aldagen has 11 investors. Key investors include Square 1 Bank, Harbert Management, Nuo Therapeutics, Piedmont Angel Network, and Intersouth Partners.
Aldagen operates through Aldagen, Inc..
Yes. Aldagen was acquired by Nuo Therapeutics in February 2012.